WALTHAM, MA • 2022-11-29

BostonGene to Present at the 2022 San Antonio Breast Cancer Symposium

5 min to read

Presentations show the application of AI and innovative technologies to uncover the role of the tumor microenvironment in breast carcinomas and highlight a BostonGene-developed and validated new homologous recombination deficiency scoring system is predictive of PARP inhibitor response
WALTHAM, MA, November 29, 2022

BostonGene today announced that four abstracts have been accepted for poster presentations for the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held December 6 - 9, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 107.

“The data we will present at SABCS demonstrates the clinical utility of BostonGene‘s AI-based molecular and immune profiling and analytics to advance and optimize outcomes for cancer patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our findings highlight the importance of a multifaceted approach to understand the composition and activity of the tumor and the microenvironment.”

Details about the abstracts selected for presentation can be found below:

Abstract Number: 1304759
Title: A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival
Date and Time: Thursday, December 8 | 7:00 AM - 8:15 AM
Location: Poster Session 4 – Hall 1
Poster Number: P4-09-02
Speaker: Nikita Kotlov, BostonGene

Using whole-transcriptome data clustering techniques, BostonGene uncovered five distinct basal-like breast cancer molecular functional portraits prognostic for survival using gene signatures from the tumor microenvironment.

Abstract Number: 1310282
Title:  An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-45
Speaker: Nikita Kotlov, BostonGene

BostonGene developed and validated a new homologous recombination deficiency (HRD) scoring system for breast cancer patients. This novel HRD score, which uses long-focal copy number alterations and ploidy rather than relying on germline mutations in the homologous recombination pathway, was predictive of PARP inhibitor response.

Abstract Number: 1310386
Title: AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas
Date and Time: Friday, December 9 | 7:00 AM - 8:15 AM
Location: Poster Session 6 – Hall 1
Poster Number: P6-04-15
Speaker: Ekaterina Postovalova, PhD, BostonGene

Leveraging a convolutional neural network, BostonGene trained and validated an image analysis platform capable of detecting tertiary lymphoid structures and the lymphocyte immune-infiltrated area on breast carcinoma H&E slides. This AI-based approach may be used to automate the traditional pathology workflow.

Abstract Number: 1310481
Title: TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Date and Time: Thursday, December 8 | 5:00 PM - 6:15 PM
Location: Poster Session 5 – Hall 1
Poster Number: P5-02-13
Speaker: Jennifer C. Keenan, Mass General Cancer Center

In this case report, BostonGene’s Tumor PortraitTM next-generation sequencing test provided orthogonal validation for two NTRK fusions, including one novel fusion, detected by cell-free DNA analysis in a metastatic triple-negative breast cancer patient.

Research conducted with Mass General Cancer Center

For more information, please visit the 2022 San Antonio Breast Cancer Symposium website. The abstracts will be published in the Abstracts2ViewTM online database at the conclusion of the symposium.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director